Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Edwards Lifesciences presented new data at New York Valves 2026, including seven-year benchmark durability data from the PARTNER 3 trial for the SAPIEN 3 platform, underscoring the long-term performance of its flagship technology. Baseline characteristics from the PROGRESS trial revealed that over 95% of moderate aortic stenosis patients were symptomatic and 70% had multiple at-risk features, supporting the strategic rationale for earlier transcatheter intervention.
Key figures
- Progress mean age
- 78
- Progress mean kccq
- 64
- Pascal patient count
- 4500
- Progress 2plus risks pct
- >70
- Progress normal lvef pct
- >90
- Progress symptomatic pct
- >95
- Partner3 durability years
- 7
- Progress low surgical risk pct
- 46
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.